- Home
- ABLV vs PRLD Comparison
ABLV vs PRLD Comparison
Compare ABLV & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- PRLD
- Stock Information
- Founded
- ABLV 2015
- PRLD 2016
- Country
- ABLV China
- PRLD United States
- Employees
- ABLV N/A
- PRLD N/A
- Industry
- ABLV
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ABLV
- PRLD Health Care
- Exchange
- ABLV Nasdaq
- PRLD Nasdaq
- Market Cap
- ABLV 48.6M
- PRLD 48.6M
- IPO Year
- ABLV N/A
- PRLD 2020
- Fundamental
- Price
- ABLV $1.09
- PRLD $0.93
- Analyst Decision
- ABLV
- PRLD Strong Buy
- Analyst Count
- ABLV 0
- PRLD 2
- Target Price
- ABLV N/A
- PRLD $4.50
- AVG Volume (30 Days)
- ABLV 14.3K
- PRLD 177.2K
- Earning Date
- ABLV 04-23-2025
- PRLD 08-11-2025
- Dividend Yield
- ABLV N/A
- PRLD N/A
- EPS Growth
- ABLV N/A
- PRLD N/A
- EPS
- ABLV N/A
- PRLD N/A
- Revenue
- ABLV $128,932,647.00
- PRLD $7,000,000.00
- Revenue This Year
- ABLV N/A
- PRLD N/A
- Revenue Next Year
- ABLV N/A
- PRLD N/A
- P/E Ratio
- ABLV N/A
- PRLD N/A
- Revenue Growth
- ABLV N/A
- PRLD N/A
- 52 Week Low
- ABLV $0.55
- PRLD $0.61
- 52 Week High
- ABLV $1.90
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- ABLV 55.98
- PRLD 59.77
- Support Level
- ABLV $0.99
- PRLD $0.77
- Resistance Level
- ABLV $1.22
- PRLD $0.85
- Average True Range (ATR)
- ABLV 0.09
- PRLD 0.07
- MACD
- ABLV 0.02
- PRLD 0.01
- Stochastic Oscillator
- ABLV 66.67
- PRLD 64.00
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.